NKT cells: Potential targets for autoimmune disease therapy?

Tissue Antigens

Volumn 59, Issue 5, 2002, Pages 353-363

  Hammond, K J L ^a   Godfrey, D I ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Autoimmunity; Cytokines; NKT cells; T lymphocytes

Indexed keywords

CD1 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 7; LYMPHOTACTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOSTATIN; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE REARRANGEMENT; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MEMORY CELL; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; T LYMPHOCYTE SUBPOPULATION;

ANIMAL; AUTOIMMUNE DISEASES; HUMAN; IMMUNOTHERAPY; KILLER CELLS, NATURAL; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTE SUBSETS; ANIMALS; HUMANS;

ANIMALIA; SCLERODERMA;

EID: 0036024567     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.590501.x     Document Type: Review

References (66)

1. Mouse CD1-specific NK1 T cells: Development, specificity, and function
2. NKT cells: Facts, functions and fallacies
3. -αβ T cells demonstrates preferential use of several Vβ genes and an invariant TCR α chain
4. - T cells
5. Close phenotypic and functional similarities between human and murine αβ T cells expressing invariant TCR α-chains
6. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes
7. TCR Vα24 Vβ11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation
8. Natural T cells in the human liver: Cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Vα24-JαQ and γδ T cell receptor bearing cells
9. + T cells
10. The CD1 system: Antigen-presenting molecules for T cell recognition of lipids and glycolipids
11. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
12. Diverse CD1d-restricted reactivity patterns of human T cells beating 'invariant' AV24BV11 TCR
13. KRN7000, a novel immunomodulator, and its antitumor activities
14. Cutting edge: Activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
15. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
16. NKT cells - Conductors of tumor immunity?
17. Auto-reactivity by design: Innate B and T lymphocytes
18. - T-Cell deficiency and IDDM in NOD/Lt mice
19. - thymocytes
20. +-like thymocytes in the NOD mouse
21. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice
22. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex
23. CD1d-restricted NKT cells: An interstrain comparison
24. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in nonobese diabetic mice
25. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10
26. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes
27. NK T cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen
28. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes
29. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes
30. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse
31. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets
32. + T cell-defective IL-4 production in the non-obese diabetic mouse
33. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection
34. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo
35. MIP-2 recruits NKT cells to the spleen during tolerance induction
36. NKT cells and tumor immunity - A double-edged sword
37. A molecular analysis of NKT cells: Identification of a class-I restricted T cell-associated molecule (CRTAM)
38. Multiple differences in gene expression in regulatory Vα24JαQ T cells from identical twins discordant for type 1 diabetes
39. Genetic models for CNS inflammation
40. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells
41. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells
42. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis
43. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis
44. Experimental allergic encephalomyelitis in inbred and outbred mice
45. + T cells that promptly produce interleukin 4
46. Natural killer-like T cells develop in SJL mice despite genetically distinct defects in NK1.1 expression and in inducible interleukin-4 production
47. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type-1 positive cells: Evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms
48. + CD1d-dependent precursor stage
49. + NK T cells associated with disease development in autoimmune-prone mice
50. Extreme Th1 bias of invariant Vα24-JαQ T cells in Type 1 diabetes
51. Multiple immuno-regulatory defects in type-1 diabetes
52. Clinical application of NKT cell assays to the prediction of type 1 diabetes
53. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis
54. + T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis
55. Increased interleukin-4 production by NK T cells in systemic lupus erythematosus
56. Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus
57. + double-negative regulatory natural killer T cells in autoimmune diseases
58. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by auto-reactive tissue damage
59. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy
60. -Vα24JαQ T cells in peripheral blood of patients with relapsing-remitting multiple sclerosis
61. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA)
62. + double-negative T cells in rheumatoid synovium
63. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide
64. + T cells from IL-7-deficient mice have a normal distribution and selection but exhibit impaired cytokine production
65. + T cells
66. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways